Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology

Table 1 Methodological quality summary: review authors' judgments about each methodological quality item for each included study.

Author (year)	Subjects included	Duration (months)	Primary outcome	Adequate sequence generation	Allocation concealment	Blinding	Incomplete outcome data	Selective outcome reporting
Van Gaal (2005)*	placebo = 305	12	Weight change	Yes	Yes	Yes	No	No
	rimonabant 5 mg = 603
	rimonabant 20 mg = 599
Després (2005)*	placebo = 342	12	Weight change	Yes	Yes	Yes	No	No
	rimonabant 5 mg = 345
	rimonabant 20 mg = 346
Pi-Sunyer (2006)*	placebo = 607	12	Weight change	Yes	Yes	Yes	No	No
	rimonabant 5 mg = 1214
	rimonabant 20 mg = 1219
Scheen (2006)*	placebo = 348	12	Weight change	Yes	Yes	Yes	No	No
	rimonabant 5 mg = 358
	rimonabant 20 mg = 339
Nissen (2008)	placebo = 417	18	Change in percent atheroma volume	Yes	Yes	Yes	No	No
	rimonabant 20 mg = 422
Van Gaal (2008)*	placebo = 168	24	Weight change	Yes	Yes	Yes	No	No
	rimonabant 5 mg = 363
	rimonabant 20 mg = 305
Soyka (2008)	placebo = 127	3	Time to first drink	Yes	Yes	Yes	No	No
	rimonabant 20 mg = 131		Time to relapse to first heavy drinking
Rosenstock (2008)	Placebo = 140	6	HbA_1c	NR	NR	Yes	No	No
	Rimonabant 20 mg = 138
Després (2009)	Placebo = 395	12	Change in HDL cholesterol and triglycerides	Yes	Yes	Yes	No	No
	Rimonabant 20 mg = 404

ISSN: 1471-230X